Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hansoh Pharmaceutical’s HS-20093, a B7-H3-targeted antibody-drug conjugate, has gained significant attention as it secures the European Medicines Agency’s Priority Medicines designation, bolstering its development in treating relapsed extensive-stage small-cell lung cancer. This follows its Breakthrough Therapy Designation by the FDA, enhancing its potential market impact. Investors may find interest in the collaboration with GlaxoSmithKline, which holds an exclusive worldwide license for the drug’s development and commercialization.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.